[Initial experiences with a new monoclonal antibody in diagnosis of malignant melanomas].
In a study of 17 patients with malignant melanomas in the extremities the sensitivity and specificity of a new monoclonal antibody directed at melanoma cells (BW 575, Behring) were investigated. The specificity was 100%, but the sensitivity 70%. In 3 cases known foci could not be detected. All nodular melanomas and their metastases were detected (9 patients). Repeated examination during the first 24 h after injection of the Tc-99m-marked antibody, and two-plane investigations made it possible to detect even small tumors less than 1 cm in diameter and subcutaneous lesions where the melanomas absorbed the antibodies. Due to its high specificity, the antibody seems to be a promising aid in deciding the operative strategy.
Omlor
G
G
Abteilung für Allgemeine Chirurgie, Abdominal- und Gefässchirurgie, Universität des Saarlandes, Homburg/Saar, BRD.
Berberich
R
R
Gross
G
G
Alexander
C
C
Feifel
G
G
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D010478:Chemotherapy, Cancer, Regional Perfusion; D005260:Female; D006801:Humans; D007866:Leg; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000188:drug therapy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D016719:Radioimmunodetection; D012878:Skin Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy; D013667:Technetium
D000911:Antibodies, Monoclonal; D013667:Technetium
Erste Erfahrungen mit einem neuen monoklonalen Antikörper in der Diagnostik maligner Melanome.